Evaluation of serum galectin-3 levels at Alzheimer patients by stages: a preliminary report
- PDF / 651,823 Bytes
- 6 Pages / 595.276 x 790.866 pts Page_size
- 50 Downloads / 146 Views
ORIGINAL ARTICLE
Evaluation of serum galectin‑3 levels at Alzheimer patients by stages: a preliminary report Tamer Yazar1,2 · Hülya Olgun Yazar3,4 · Murat Cihan4 Received: 21 April 2020 / Accepted: 17 August 2020 © Belgian Neurological Society 2020
Abstract Background and Aims Neuroinflammation has a critic role in the pathophysiology of neurological diseases. The activation of microglia is the main actor in this process. The aim of this study to collect data on the role of microglial activation in the etiology, and the possible continuum at the stage of disease through the evaluation of serum galectin-3 levels in patients with Alzheimer’s disease (AD). Methods This was a prospective and cross-sectional study conducted on patients who were diagnosed as having AD using the criteria of the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA) and stages determined with the scales of Clinical Dementia Rating (CDR) and Mini-Mental State Examination (MMSE) with healthy controls. Results In our study, we studied 118 people, 57 with AD and 61 healthy people as a control group. In the AD patient group, serum galectin-3 levels were higher compared with the control group (p = 0.003). There were no significant differences in either group in other collected parameters (p > 0.05). It was observed that in all patients with AD, parallel to the stage of the disease, serum galectin-3 levels, patience’s age, and duration of disease were statically and significantly increased (p
Data Loading...
